Payment overview · 2025
General Payments
$606.62
32 reported records · 18 companies
Healthcare provider profile · identity verified
Scott R Capen, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREENFIELD, IN · NPI 1386646925
Verified facts
What the public records show
CMS Open Payments records show Scott R Capen, MD received $606.62 in general payments during 2025 across 32 reported records.
PFIZER INC. accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $98.06 | 16.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $79.52 | 13.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.74 | 11.3% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $47.24 | 7.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.04 | 7.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.23 | 7.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.81 | 6.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.19 | 4.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.94 | 3.3% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $19.82 | 3.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.16 | 3.2% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $18.37 | 3.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.87 | 2.6% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.17 | 2.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.28 | 2.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.01 | 2.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.74 | 2.3% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $8.43 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $606.62 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $83.82 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $54.54 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $54.35 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $47.24 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.62 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $34.22 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.28 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 222 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 64 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 134 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 114 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 28 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 141 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
89 | 19 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
35 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
28 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
141 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
114 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
73 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
222 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1354 | 350 |
| Levothyroxine Sodium | Levothyroxine Sodium | 608 | 138 |
| Omeprazole | Omeprazole | 596 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 495 | 128 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 457 | 72 |
| Gabapentin | Gabapentin | 431 | 93 |
| Losartan Potassium | Losartan Potassium | 426 | 121 |
| Lisinopril | Lisinopril | 409 | 109 |
| Metformin Hcl | Metformin Hcl | 354 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 342 | 97 |
| Valsartan | Valsartan | 337 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 327 | 77 |
| Alprazolam | Alprazolam | 323 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 304 | 69 |
| Alendronate Sodium | Alendronate Sodium | 295 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 267 | 68 |
| Tramadol Hcl | Tramadol Hcl | 246 | 56 |
| Montelukast Sodium | Montelukast Sodium | 223 | 62 |
| Eliquis | Apixaban | 222 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 219 | 64 |
| Furosemide | Furosemide | 203 | 60 |
| Buspirone Hcl | Buspirone Hcl | 201 | 48 |
| Simvastatin | Simvastatin | 199 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 194 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 194 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 54 |
| Prednisone | Prednisone | 166 | 85 |
| Allopurinol | Allopurinol | 157 | 38 |
| Meloxicam | Meloxicam | 156 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 152 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 151 | 30 |
| Sertraline Hcl | Sertraline Hcl | 150 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 36 |
| Bupropion Xl | Bupropion Hcl | 145 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 141 | 26 |
| Trazodone Hcl | Trazodone Hcl | 140 | 31 |
| Clonazepam | Clonazepam | 139 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 33 |
| Jardiance | Empagliflozin | 134 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 39 |
| Xarelto | Rivaroxaban | 124 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 117 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 30 |
| Mounjaro | Tirzepatide | 114 | 23 |
| Potassium Chloride | Potassium Chloride | 110 | 32 |
| Pregabalin | Pregabalin | 110 | 17 |
| Glimepiride | Glimepiride | 102 | 27 |
| Ozempic | Semaglutide | 102 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 21 |
| Metformin Hcl Er | Metformin Hcl | 90 | 27 |
| Synthroid | Levothyroxine Sodium | 89 | 19 |
| Repatha Sureclick | Evolocumab | 83 | 17 |
| Spironolactone | Spironolactone | 82 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 77 | 19 |
| Cefuroxime | Cefuroxime Axetil | 75 | 69 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 75 | 22 |
| Dutasteride | Dutasteride | 74 | 25 |
| Rybelsus | Semaglutide | 73 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 20 |
| Lorazepam | Lorazepam | 70 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 69 | 19 |
| Chlorthalidone | Chlorthalidone | 68 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 19 |
| Cephalexin | Cephalexin | 67 | 51 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 20 |
| Farxiga | Dapagliflozin Propanediol | 64 | 17 |
| Atenolol | Atenolol | 63 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 58 | 11 |
| Ondansetron Odt | Ondansetron | 58 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | 13 |
| Chlorzoxazone | Chlorzoxazone | 56 | 19 |
| Lansoprazole | Lansoprazole | 56 | 15 |
| Eszopiclone | Eszopiclone | 55 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 55 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 45 |
| Torsemide | Torsemide | 52 | 13 |
| Carvedilol | Carvedilol | 51 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 51 | suppressed |
| Temazepam | Temazepam | 51 | suppressed |
| Mirtazapine | Mirtazapine | 50 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 11 |
| Estradiol | Estradiol | 49 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 49 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 12 |
| Klor-Con M20 | Potassium Chloride | 48 | 11 |
| Sucralfate | Sucralfate | 48 | 13 |
| Clonidine Hcl | Clonidine Hcl | 47 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 47 | suppressed |
| Nifedipine Er | Nifedipine | 47 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 29 |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Topiramate | Topiramate | 43 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 14 |
| Terazosin Hcl | Terazosin Hcl | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 11 |
| Vascepa | Icosapent Ethyl | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 33 |
| Nystatin | Nystatin | 38 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 28 |
| Myrbetriq | Mirabegron | 35 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 28 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Azithromycin | Azithromycin | 33 | 30 |
| Celecoxib | Celecoxib | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Famotidine | Famotidine | 32 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 18 |
| Fluconazole | Fluconazole | 31 | 19 |
| Spiriva Respimat | Tiotropium Bromide | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 30 | suppressed |
| Acyclovir | Acyclovir | 29 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 29 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Colchicine | Colchicine | 29 | 13 |
| Methylprednisolone | Methylprednisolone | 29 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 26 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 23 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 12 |
| Lagevrio (Eua) | Molnupiravir | 19 | 19 |
| Anastrozole | Anastrozole | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | 11 |
| Fyavolv | Norethindrone Ac/Eth Estradiol | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Klayesta | Nystatin | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 12 |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Voquezna | Vonoprazan Fumarate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $606.62 · 32 records | PFIZER INC. | ABRYSVO, AIRSUPRA, Azstarys, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Jornay PM, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, QUTENZA, REPATHA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, Veozah, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error